USCDI Task Force 2021 Call #2

Steven Lane, Co-Chair
Terry O’Malley, Co-Chair

February 9, 2021
Meeting Agenda

• Call to Order/Roll Call
• Review of Reformatted Task Force Charges
• Out of Scope Tasks – Level 1/Comment Elements
  • Tasks 1a and 1b
• TF Schedule/Next Meeting
• Public Comment
• Adjourn
## Task Force Roster

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Lane (Co-Chair)</td>
<td>Sutter Health</td>
</tr>
<tr>
<td>Terry O’Malley (Co-Chair)</td>
<td>Individual</td>
</tr>
<tr>
<td>Ricky Bloomfield</td>
<td>Apple</td>
</tr>
<tr>
<td>Hans Buitendijk</td>
<td>Cerner</td>
</tr>
<tr>
<td>Valerie Grey</td>
<td>New York eHealth Collaborative</td>
</tr>
<tr>
<td>Leslie Kelly Hall</td>
<td>Engaging Patient Strategy</td>
</tr>
<tr>
<td>Jim Jirjis</td>
<td>HCA Healthcare</td>
</tr>
<tr>
<td>Ken Kawamoto</td>
<td>University of Utah Health</td>
</tr>
<tr>
<td>Leslie Lenert</td>
<td>Medical University of South Carolina</td>
</tr>
<tr>
<td>Clement McDonald</td>
<td>National Library of Medicine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Miri</td>
<td>University of Texas at Austin, Dell Medical School and UT Health Austin</td>
</tr>
<tr>
<td>Brett Oliver</td>
<td>Baptist Health</td>
</tr>
<tr>
<td>Mark Savage</td>
<td>University of California’s Center for Digital Health Innovation</td>
</tr>
<tr>
<td>Michelle Schreiber</td>
<td>CMS</td>
</tr>
<tr>
<td>Sasha TerMaat</td>
<td>Epic</td>
</tr>
<tr>
<td>Andrew Truscott</td>
<td>Accenture</td>
</tr>
<tr>
<td>Sheryl Turney</td>
<td>Anthem, Inc.</td>
</tr>
<tr>
<td>Daniel Vreeman</td>
<td>RTI International</td>
</tr>
<tr>
<td>Denise Webb</td>
<td>Indiana Hemophilia and Thrombosis Center</td>
</tr>
</tbody>
</table>
Task Force Charge

Overarching charge:

Review and feedback on the Draft USCDI Version 2 content and process

Specific charges:

1. Evaluate Draft USCDI v2 and provide HITAC with recommendations for:
   1a. Data classes and elements from USCDI v1 including applicable standards version updates
   1b. New data classes and elements from Draft USCDI v2 including applicable standards
   1c. Level 2 data classes and elements not included in Draft USCDI v2
   Due: April 15, 2021

2. Evaluate the USCDI expansion process and provide HITAC with recommendations for:
   2a. ONDEC submission system improvements
   2b. Evaluation criteria and process used to assign levels to submitted data classes and elements
   2c. Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2
   Due: September 9, 2021

3. Recommend ONC priorities for USCDI version 3 submission cycle
   Due: September 9, 2021
Draft USCDI v2
Public Comment Period Tasks

Tasks Out of Scope for TF

Evaluate Level 1 and Comment Data Elements not included in Level 2
- Process underway to engage between submitting stakeholders and ONC
- TF members may participate in this comment process individually
Task Force Charge 1a

1. Evaluate Draft USCDI v2 and provide HITAC with recommendations for:
   1a - Data classes and elements from USCDI v1 including applicable standards version updates
   1b - New data classes and elements from Draft USCDI v2 including applicable standards
   1c - Level 2 data classes and elements not included in Draft USCDI v2

2. Evaluate the USCDI expansion process and provide HITAC with recommendations for:
   2a - ONDEC submission system improvements
   2b - Evaluation criteria and process used to assign levels to submitted data classes and elements
   2c - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2

3. Recommend ONC priorities for USCDI version 3 submission cycle

Due:
- April 15, 2021
- September 9, 2021
Draft USCDI version 2
Updated Applicable Standards Versions

• USCDI v1
  • RxNorm - January 6, 2020
  • SNOMED CT - September 2019
  • LOINC 2.67
  • ICD-10-PCS 2020
  • CVX - January 31, 2020
  • Vaccine NDC Linker - January 31, 2020
  • CPT 2020

• Draft USCDI v2
  • RxNorm - January 4, 2021
  • SNOMED CT - September 2020
  • LOINC 2.69
  • ICD-10-PCS 2021
  • CVX - November 16, 2020
  • Vaccine NDC Linker - November 13, 2020
  • CPT 2021
Draft USCDI version 2
Reclassified Clinical Note Data Elements

- Clinical Notes
  - Consultation Note
  - Discharge Summary Note
  - History & Physical
  - Procedure Note
  - Progress Note
  - Diagnostic Imaging Narrative
  - Laboratory Report Narrative
  - Pathology Report Narrative

- Diagnostic Imaging
  - Diagnostic Imaging Narrative

- Laboratory
  - Laboratory Report Narrative
  - Pathology Report Narrative
Task 1a – Data Elements and Classes from USCDI v1

- Comments
- Additions
- Clarifications/Modifications
Draft USCDI v2

Allergies and Intolerances
- Substance (Medication)
- Substance (Drug Class)
- Reaction

Assessment and Plan of Treatment
- Assessment and Plan of Treatment

Care Team Members
- Care Team Members
- Provider Name
- Provider Identifier

Clinical Notes
- Consultation Note
- Discharge Summary Note
- History & Physical
- Procedure Note
- Progress Note

Diagnostic Imaging
- Diagnostic Imaging Order
- Diagnostic Imaging Report
- Diagnostic Imaging Narrative

Encounter Information
- Encounter Type
- Encounter Diagnosis
- Encounter Time

Goals
- Patient Goals

Health Concerns
- Health Concerns

Immunizations
- Immunizations

Laboratory
- Tests
- Values/Results
- Laboratory Report Narrative
- Pathology Report Narrative

Medications
- Medications

Patient Demographics
- First Name
- Last Name
- Previous Name
- Middle Name (incl. middle initial)
- Suffix
- Birth Sex
- Date of Birth
- Race
- Ethnicity
- Preferred Language
- Current Address
- Previous Address
- Phone Number
- Phone Number Type
- Email Address

Problems
- Problems
- Date of Diagnosis
- Date of Resolution

Procedures
- Procedures

Provenance
- Author Time Stamp
- Author Organization

Smoking Status
- Smoking Status

Unique Device Identifier(s) for a Patient’s Implantable Device(s)
- Unique Device Identifier(s) for a Patient’s Implantable Device(s)

Vital Signs
- Diastolic Blood Pressure
- Systolic Blood Pressure
- Body Height
- Body Weight
- Heart Rate
- Respiratory Rate
- Body Temperature
- Pulse Oximetry
- Inhaled Oxygen Concentration
- BMI Percentile (2-20 Years)
- Weight-for-length Percentile (Birth-36 Months)
- Occipital-frontal Head Circumference Percentile (Birth-36 Months)

Key
- New Data Class or Element
- Data Element reclassified
Task Force Charge

1. Evaluate Draft USCDI v2 and provide HITAC with recommendations for:
   1a - Data classes and elements from USCDI v1 including applicable standards version updates
   1b - New data classes and elements from Draft USCDI v2 including applicable standards
   1c - Level 2 data classes and elements not included in Draft USCDI v2

2. Evaluate the USCDI expansion process and provide HITAC with recommendations for:
   2a - ONDEC submission system improvements
   2b - Evaluation criteria and process used to assign levels to submitted data classes and elements
   2c - Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2

3. Recommend ONC priorities for USCDI version 3 submission cycle

Due
April 15, 2021

Due
September 9, 2021
Draft USCDI version 2
New Data Classes and Elements

• Care Team Members
  • Provider Name
  • Provider Identifier

• Diagnostic Imaging
  • Diagnostic Imaging Order
  • Diagnostic Imaging Report

• Encounter Information
  • Encounter Type
  • Encounter Diagnosis
  • Encounter Time

• Problems
  • Date of Diagnosis
  • Date of Resolution
Task 1b – New Data Elements and Classes

• Comments

• Additions

• Clarifications/Modifications
USCDI Version Update Process

2020
- Submission & Review Period - v2
  - ONC v2 Draft Prep
  - HITAC v2 Public Comment v2
- USCDI v1 Final

2021
- Submission & Review Period - v3
  - ONC v2 Draft Prep
  - HITAC v2 Public Comment v2
  - ONC Review/Approval
- USCDI v2 Final
  - Considered for 2021 SVAP

2022
- Submission & Review Period - v4
  - ONC v3 Draft Prep
  - HITAC v3 Public Comment v3
  - ONC Review/Approval
- USCDI v3 Draft
- USCDI v3 Final
  - Considered for 2022 SVAP
Next TF Meetings

- February 16, 2021  10:30 a.m. - 12:00 p.m. ET
- February 23, 2021  10:30 a.m. - 12:00 p.m. ET
- March 2, 2021      10:30 a.m. - 12:00 p.m. ET
- March 9, 2021      10:30 a.m. - 12:00 p.m. ET
Public Comment

To make a comment please call:
Dial: 1-877-407-7192

(Once connected, press “*1” to speak)

All public comments will be limited to three minutes.

You may enter a comment in the “Public Comment” field below this presentation.

Or, email your public comment to onc-hitac@accelsolutionsllc.com.

Written comments will not be read at this time, but they will be delivered to members of the Task Force and made part of the Public Record.
Meeting Adjourned